Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Earnings release
confidence 99%
filed 2026-08-13
Item 2.02
Tapestry issued a press release on August 13, 2026 announcing financial results for its fourth fiscal quarter and full year ended June 27, 2026. The disclosure includes detailed financial highlights (revenue of $8.0 billion, GAAP diluted EPS of $7.27, non-GAAP diluted EPS of $7.05), brand performance metrics, regional results, and forward guidance for fiscal 2027. This is a standard quarterly/annual earnings release disclosure under Item 2.02, material to investors assessing the company's financial performance and outlook.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-13
Item 2.02
Grace Therapeutics issued a press release on August 13, 2026, announcing financial results for the three months ended June 30, 2026, including net loss of $15.8 million (vs. $3.4 million prior year), a $13.5 million impairment of IPR&D for GTx-101 and GTx-102, and cash runway through end of 2028. The disclosure is furnished under Item 2.02 "Results of Operations and Financial Condition" with the press release attached as Exhibit 99.1, which is the standard format for earnings releases on Form 8-K.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-13
Item 2.02
PDS Biotechnology issued a press release on August 13, 2026 announcing financial results for the quarter ended June 30, 2026, including net loss of $9.8 million, operating expenses, interest expense, and cash balance of $5.6 million. The filing includes condensed consolidated statements of operations and selected balance sheet data, which are standard components of a quarterly earnings disclosure under Item 2.02.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-08-13
EX-99.1
This is a press release announcing Brookfield Corporation's financial results for the quarter ended June 30, 2026. The exhibit discloses quarterly and last-twelve-months earnings metrics including net income ($703M for Q2 2026), distributable earnings ($1.548B for Q2), and earnings per share ($0.14 diluted), along with detailed operating results by business segment. The 15% increase in earnings per share and record fundraising of $77 billion are material developments affecting investor assessment of the registrant's financial performance and capital deployment capacity.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-08-13
EX-99.1
This is a press release announcing Brookfield Wealth Solutions' financial results for the quarter and six months ended June 30, 2026. The exhibit discloses key financial metrics including total assets ($205.7 billion), distributable operating earnings ($488 million for Q2, $926 million for six months), net income ($149 million for Q2, net loss of $453 million for six months), and earnings per share ($0.07 for Q2, $0.14 for six months). The release includes consolidated balance sheets, statements of operations, and reconciliations of non-GAAP measures, along with management commentary from the CEO on business performance and strategic initiatives. This is a discrete earnings announcement, not a periodic financial report filing.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-13
Item 2.02
Aebi Schmidt issued a press release on August 13, 2026, announcing its financial results for the quarter ended June 30, 2026 (Q2 2026). The disclosure reports key financial metrics including Net Sales of $496m (up 9% YoY), Net Income of $10.5m (up $18m YoY), and Adjusted EBITDA of $42.1m (up 22% YoY), along with full-year 2026 guidance. This is a standard quarterly earnings release furnished as Exhibit 99.1, which is the typical form and substance of an earnings_release event under Item 2.02.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-08-13
EX-99.1
This exhibit is a press release disclosing Golar LNG's interim financial results for the second quarter and first half of 2026, including Q2 2026 net income of $38 million, Adjusted EBITDA of $127 million, and Total Golar Cash of $908 million. The document presents detailed financial tables, segment reporting, and balance sheet metrics typical of a quarterly earnings announcement. While the release also discusses operational highlights and capital projects (FLNG orders, contracts), the primary disclosure is the quarterly financial results, making this an earnings_release rather than a periodic_quarterly report.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-08-13
EX-99.1
This is a press release disclosing Osisko Gold's Q2 2026 financial and operating results for the three months ended June 30, 2026. The document reports cash position (~$837.3 million), revenues ($32.7 million), operating income ($8.1 million), and material project developments at the Cariboo Gold Project and Tintic Project. The filing explicitly states "Osisko Gold Group Inc. reports its financial and operating results for the three months ended June 30, 2026" and includes consolidated financial statements and MD&A, making this a standard quarterly earnings release.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-08-13
EX-99.1
This exhibit is a press release announcing MediWound's second quarter 2026 financial results, including revenue of $3.1 million, operating loss of $9.5 million, and net loss of $7.4 million. The document explicitly states "MediWound Reports Second Quarter 2026 Financial Results" and includes unaudited condensed consolidated financial statements (balance sheet, income statement, and cash flows). This is a discrete earnings announcement, not a periodic financial report filing, and is material to investors assessing the company's financial performance and cash burn trajectory.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-13
Item 2.02
X-Energy issued a press release on August 13, 2026 reporting financial results for the quarter ended June 30, 2026, disclosing revenues and grant income of $54.6 million (154% increase YoY), operating expenses, cash flow metrics, and liquidity position. The filing explicitly states "On August 13, 2026, X-Energy, Inc. (the "Company") issued a press release reporting its financial results for the quarter ended June 30, 2026" and furnishes the press release as Exhibit 99.1, which is the standard format for earnings releases under Item 2.02.
View raw filing on EDGAR →
6-K
Earnings release
confidence 98%
filed 2026-08-13
EX-99.1
This exhibit is a press release announcing JD.com's unaudited financial results for the second quarter and interim six months ended June 30, 2026. The document discloses net revenues of RMB346.4 billion, operating income, net income, diluted EPS, and other key financial metrics for both the quarterly and year-to-date periods, along with segment performance and business highlights. This is a classic earnings release disclosing quarterly and interim financial results.
View raw filing on EDGAR →
6-K
Earnings release
confidence 98%
filed 2026-08-13
EX-99.1
This is a press release announcing Birkenstock's fiscal third quarter 2026 financial results, including revenue of EUR 720 million (up 13% reported, 15% constant currency), net profit of EUR 110 million, and Adjusted EBITDA of EUR 242 million. The company also raised full-year FY26 guidance for revenue growth to 15% in constant currency and Adjusted EBITDA to at least EUR 710 million. This is a discrete earnings announcement, not a periodic financial report.
View raw filing on EDGAR →
8-K
Earnings release
confidence 97%
filed 2026-08-13
Item 2.02
SBC Medical Group Holdings issued a press release on August 13, 2026 announcing consolidated financial results for the second quarter ended June 30, 2026, including quarterly revenue of $49 million (up 13% YoY), net income of $11 million (up 335% YoY), and adjusted EBITDA of $20 million (up 32% YoY), along with detailed financial tables and management commentary.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-13
Item 2.02
Lithium Americas issued a press release on August 13, 2026 announcing its financial and operational results for Q2 2026 (three months ended June 30, 2026), including unaudited condensed consolidated interim financial statements showing net income of $6.3 million for YTD Q2 2026 versus a loss of $24.8 million in YTD Q2 2025, alongside operational updates on the Thacker Pass lithium project.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-13
Item 2.02
Aveanna Healthcare disclosed Q2 2026 financial results showing revenue of $670.5 million (13.7% YoY increase), net income of $40.3 million, and Adjusted EBITDA of $95.4 million, along with raised full-year 2026 guidance for revenue (greater than $2.68 billion) and Adjusted EBITDA (greater than $365 million).
View raw filing on EDGAR →
6-K
Earnings release
confidence 98%
filed 2026-08-13
EX-99.1
This is a press release announcing Paysafe's second quarter 2026 financial results, including revenue of $447.4 million (4% growth), net loss of $58.9 million, adjusted net income of $23.1 million, and adjusted EBITDA of $102.8 million. The document includes detailed consolidated financial statements (income statement, balance sheet, cash flows) and updated full-year 2026 guidance. This is a discrete earnings announcement, not a periodic financial report filing, and is material to investors assessing the company's operational and financial performance.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-13
Item 2.02
This is a clear earnings release disclosing quarterly financial results for the three months ended June 30, 2026. The filing explicitly states "reported its financial and operational results for the three months and year ended June 30, 2026" with a press release furnished as Exhibit 99.1. The exhibit contains condensed consolidated balance sheets, statements of income/loss, and detailed financial highlights including revenue ($120k vs $7k), operating loss ($2.9M vs $3.6M), and net loss ($28k vs net income of $1.7M), along with business highlights and management commentary typical of a quarterly earnings disclosure.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-13
Item 2.02
SOLV Energy issued a press release on August 13, 2026 announcing financial results for the quarter ended June 30, 2026, disclosing Q2 2026 revenue of $951 million (77% YoY growth), net income of $67 million, and updated full-year 2026 guidance. The filing explicitly states this is Item 2.02 (Results of Operations and Financial Condition) with the press release furnished as Exhibit 99.1, which is the standard format for earnings releases.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-13
Item 2.02
LENSAR issued a press release on August 13, 2026 announcing financial results for the fiscal quarter ended June 30, 2026, disclosing Q2 2026 revenue of $16.5M (+18% YoY), recurring revenue of $13.7M (+20% YoY), net income of $3.5M (vs. loss of $1.8M in Q2 2025), and Adjusted EBITDA of $3.6M (vs. loss of $0.3M in Q2 2025). The press release is furnished as Exhibit 99.1 and constitutes a standard quarterly earnings disclosure under Item 2.02.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-13
Item 2.02
Parabilis Medicines reported Q2 2026 financial results, including a net loss of $52.5M, R&D expenses of $39.4M, G&A expenses of $11.7M, and cash position of $1.1B. The disclosure also included material business updates on zolucatetide advancement and a $125M Regeneron collaboration.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-13
Item 2.02
This is a clear earnings release disclosing Legence Corp.'s Q2 2026 financial results, including record quarterly revenues of $1.26 billion (111% increase YoY), adjusted EBITDA of $154.6 million (114% increase YoY), and raised full-year 2026 guidance. The press release is furnished as Exhibit 99.1 and is the primary disclosure under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings announcements.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-13
Item 2.02
enCore Energy issued a press release on August 13, 2026 announcing its financial results for the second quarter ended June 30, 2026, disclosing net loss per share of $0.19 versus $0.16 for the same period in 2025, uranium deliveries, operating margins, extraction volumes, and liquidity metrics. This is a standard quarterly earnings release furnished under Item 2.02 of Form 8-K, with the full text attached as Exhibit 99.1.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-13
Item 2.02
This is a clear earnings release disclosing Falcon's Beyond Global's financial results for the second quarter ended June 30, 2026. The filing explicitly states "Falcon's Beyond Reports Second Quarter 2026 Financial Results" and includes consolidated revenue of $5.6 million, net loss of $0.3 million, and detailed financial statements (balance sheet, income statement, and cash flow statement). The press release is furnished as Exhibit 99.1 and is the core content of Item 2.02, which is the standard Item for earnings disclosures.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-13
Item 2.02
This is a quarterly earnings release for Q2 2026 disclosing financial results including total revenue of $33.4 million, net product revenue of $30.8 million, and net loss of $67.0 million. The filing explicitly states the company "announced its financial results for the quarter ended June 30, 2026" with the full press release furnished as Exhibit 99.1, which is the standard format for Item 2.02 earnings disclosures. The release also includes forward guidance for full-year 2026 revenue and expense ranges.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-13
Item 2.02
MiNK Therapeutics announced its financial results for the quarter ended June 30, 2026, via press release furnished as Exhibit 99.1. The disclosure includes quarterly net loss ($3.1 million vs. $4.2 million prior year), cash position ($8.8 million), and per-share loss metrics ($0.62 vs. $1.06 prior year), along with clinical updates on the lead program agenT-797. This is a standard quarterly earnings release under Item 2.02, material to investors assessing the company's financial condition and clinical progress.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-13
Item 2.02
The filing discloses Pyxis Oncology's financial results for the quarter ended June 30, 2026, including detailed condensed consolidated statements of operations and balance sheets. The press release (Exhibit 99.1) announces Q2 2026 financial results with specific metrics: net loss of $25.3 million ($0.40 per share), R&D expenses of $16.1 million, and cash position of $34.5 million as of June 30, 2026. This is a standard quarterly earnings disclosure under Item 2.02, material to investors assessing the company's financial condition and burn rate.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-13
Item 2.02
Accelerant Holdings issued a press release on August 13, 2026 disclosing Q2 2026 financial results ended June 30, 2026, including revenue of $356.9 million, net income of $80.0 million, and adjusted EBITDA of $93.1 million.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-13
Item 2.02
Candel Therapeutics announced its financial results for the quarter ended June 30, 2026, on August 13, 2026, with the full press release furnished as Exhibit 99.1. The disclosure includes quarterly R&D expenses ($19.8M vs. $7.0M YoY), G&A expenses ($6.9M vs. $4.2M YoY), net loss ($38.9M vs. $4.8M YoY), and cash position ($201.6M), along with operational highlights. This is a standard quarterly earnings release disclosing results of operations and financial condition under Item 2.02.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-13
Item 2.02
Ondas Inc. issued a press release on August 13, 2026, announcing its financial and operating results for Q2 2026 ended June 30, 2026. The disclosure reports record revenue of $83.8 million (67% QoQ growth, 13-fold YoY growth), gross profit, backlog of $613 million reported ($757 million pro forma), and raised full-year 2026 revenue guidance to $525–$550 million. This is a standard quarterly earnings release furnished as Exhibit 99.1 under Item 2.02, materially affecting investor assessment of the company's financial performance and outlook.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-13
Item 2.02
This is a clear earnings release for Q2 2026 ended June 30, 2026. The filing discloses financial results including cash position ($153.8M), revenue ($2.1M), operating expenses ($33.2M), and net loss ($30.2M per share), along with business updates on clinical programs (RECLAIM-LN, FT839, FT836) and corporate developments (Laura Hamill board appointment). The press release is attached as Exhibit 99.1 and covers both financial results and material operational milestones.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-08-13
EX-99.1
The exhibit is a press release disclosing PLDT Inc.'s unaudited consolidated financial results for the six months ended June 30, 2026, including gross service revenues of ₱108.7 billion (up 2%), consolidated EBITDA of ₱56.1 billion (up 1%), and core income of ₱17.3 billion. This is a discrete earnings announcement, not a periodic financial report filing, and would materially affect a reasonable investor's assessment of the registrant's financial performance and operational trends.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-13
Item 2.02
ARS Pharmaceuticals disclosed its financial results for the quarter ended June 30, 2026 via press release attached as Exhibit 99.1, including Q2 2026 net product revenue of $26.2 million, total revenue of $33.7 million, operating expenses of $82.3 million, and net loss of $62.3 million. This is a standard quarterly earnings release disclosure under Item 2.02, material to investors assessing the company's commercial progress with neffy and financial trajectory.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-13
Item 2.02
CV Sciences disclosed its second quarter 2026 financial results on August 13, 2026, reporting revenue of $3.0 million (down 17.5% year-over-year), gross margin of 48.6%, operating loss of $0.3 million, and net loss of $0.775 million, along with consolidated financial statements and non-GAAP reconciliations.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-13
Item 2.02
Kyntra Bio issued a press release on August 13, 2026 announcing financial results for the quarter ended June 30, 2026, including revenue, net income per share, and cash position. The filing discloses condensed consolidated balance sheets and statements of operations for the second quarter and six-month periods, which are typical components of an earnings release. This is a standard quarterly financial results disclosure under Item 2.02.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-13
Item 2.02
This is a press release announcing Eikon Therapeutics' second quarter 2026 financial results, including R&D expenses ($75.5M), G&A expenses ($17.9M), net loss ($88.4M), and cash position ($531.2M as of June 30, 2026). The disclosure is furnished under Item 2.02 (Results of Operations and Financial Condition) and includes both financial metrics and clinical/corporate updates. This is a standard quarterly earnings release material to investors assessing the company's financial condition and cash runway.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-13
Item 2.02
4DMT disclosed its Q2 2026 financial results via a press release furnished as Exhibit 99.1 under Item 2.02. The filing includes a complete Statements of Operations showing revenue of $3.8 million, R&D expenses of $68.3 million, and a net loss of $72.9 million for the three months ended June 30, 2026, along with balance sheet data and cash position information. This is a standard quarterly earnings release for a public biotechnology company.
View raw filing on EDGAR →
8-K
Earnings release
confidence 97%
filed 2026-08-13
Item 2.02
Midera Food Processing issued its Q2 2026 earnings release (quarter ended July 4, 2026) reporting net sales of $245.4 million (up 13.2% year-over-year), net earnings of $10.8 million, and raised full-year 2026 guidance. This is the company's first earnings report as an independent public company following its July 6, 2026 separation from Middleby.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-13
Item 2.02
This is a clear earnings release for Q2 2026 filed under Item 2.02 (Results of Operations and Financial Condition). The press release discloses quarterly financial results including R&D expenses ($18.2M), G&A expenses ($4.6M), net loss ($31.6M or $0.27 per share), and cash position ($88.8M), along with business highlights regarding tegoprubart clinical development. The filing explicitly states it is "furnished to comply with Item 2.02 of Form 8-K" and includes condensed consolidated financial statements.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-13
Item 2.02
The filing discloses Genasys Inc.'s fiscal Q3 2026 financial results for the quarter ended June 30, 2026, issued via press release on August 13, 2026. The disclosure includes revenue ($7.3M vs. $9.9M prior year), gross margin (57.1% vs. 26.3%), GAAP net loss ($4.7M vs. $6.5M), and EPS ($0.10 loss vs. $0.14 loss), along with consolidated balance sheet and statements of operations. This is a standard quarterly earnings release material to investors' assessment of the company's financial performance and condition.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-13
Item 2.02
This is a clear earnings release disclosing Arcadia Biosciences' financial results for Q2 and H1 2026. The press release (Exhibit 99.1) announces quarterly revenues, operating expenses, net loss per share, and cash position, with supporting financial statements (balance sheet, income statement, cash flow statement) in Exhibit 99.2. The Item 2.02 disclosure and attached exhibits are the standard format for quarterly earnings announcements.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-13
Item 2.02
This is a standard quarterly earnings release for Q2 2026 ended June 30, 2026. The filing discloses financial results including cash position ($57.2 million), R&D expenses ($2.8 million), G&A expenses ($2.4 million), and net loss ($4.7 million or $(0.04) per share), along with condensed consolidated balance sheets and statements of operations. The press release is attached as Exhibit 99.1 and filed under Item 2.02, which is the standard Item for results of operations and financial condition disclosures.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-13
Item 2.02
This is a clear earnings release disclosing GrabAGun's preliminary financial results for Q2 2026 (three and six months ended June 30, 2026). The press release reports net revenues of $23.2 million (up 9.4% YoY), gross profit margin expansion to 13.5%, and net loss of $1.8 million for the quarter. The filing explicitly incorporates the press release by reference under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings disclosures. The disclosure includes detailed financial statements and operational metrics that would materially affect a reasonable investor's assessment of the company's performance.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-13
Item 2.02
This is a standard earnings release disclosing Q2 2026 financial results for Invivyd, Inc., including PEMGARDA net product revenue of $14.3 million (21% growth YoY), R&D expenses of $29.4 million, SG&A expenses of $29.5 million, and a net loss of $44.4 million. The press release also highlights recent business developments including clinical trial progress on VYD2311. The filing explicitly states this is furnished pursuant to Item 2.02 (Results of Operations and Financial Condition) with the press release attached as Exhibit 99.1.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-13
Item 2.02
Item 2.02 discloses Rani Therapeutics' financial results for the three and six months ended June 30, 2026, including a press release furnished as Exhibit 99.1. The filing reports contract revenue of $1.7 million (Q2 2026 vs. $0 in Q2 2025), net loss of $8.4 million (Q2 2026 vs. $11.2 million in Q2 2025), and cash position of $53.4 million as of June 30, 2026. This is a standard quarterly earnings disclosure with consolidated financial statements and operational metrics material to investor assessment of the company's financial condition and progress.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-13
Item 2.02
Assembly Biosciences issued a press release on August 13, 2026 announcing financial results for the quarter ended June 30, 2026, including revenue of $13.4 million, R&D expenses of $14.9 million, and a net loss of $3.9 million ($0.20 per share). The filing includes condensed consolidated balance sheets and statements of operations with comparative periods, which is the standard format for quarterly earnings disclosures under Item 2.02.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-13
Item 2.02
This Item 2.02 discloses Celcuity's financial results for Q2 2026 (ended June 30, 2026) via a press release furnished as Exhibit 99.1. The filing reports net loss of $78.9 million ($1.44 per share) versus $45.3 million ($1.04 per share) in the prior year, along with operating expenses, R&D and SG&A breakdowns, and cash position. This is a standard quarterly earnings release disclosure, material to investors assessing the company's financial performance and cash runway (expected to finance operations into 2029).
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-13
The 8-K discloses under Item 2.02 (Results of Operations and Financial Condition) that AleAnna issued a press release on August 13, 2026 announcing financial results for Q2 2026. The press release reports net income of $3.8 million and Adjusted EBITDA of $4.1 million for the quarter, along with detailed consolidated statements of operations and balance sheets. This is a standard quarterly earnings release, material to investors assessing the company's financial performance and operational progress at its Longanesi and Gradizza production assets.
View raw filing on EDGAR →
8-K
Earnings release
confidence 94%
filed 2026-08-13
Item 2.02
Chicago Atlantic BDC issued a press release on August 13, 2026 announcing its financial results for the second quarter ended June 30, 2026, including net investment income of $7.7 million ($0.34 per share), operating highlights, balance sheet data, and portfolio activity. The earnings presentation was disseminated in connection with a conference call on the same date.
View raw filing on EDGAR →
6-K
Earnings release
confidence 75%
filed 2026-08-13
EX-99.1
This press release announces Cellebrite's second-quarter 2026 financial results, including ARR of $507.8M (up 21% YoY), revenue of $131.1M (up 16% YoY), and adjusted EBITDA of $31.8M. While the release also discloses a CEO succession (Shiven Ramji succeeding Thomas E. Hogan), the primary substance is the earnings announcement with detailed financial metrics and forward guidance. The company explicitly "lowered full-year 2026 ARR and revenue outlook" while raising adjusted EBITDA targets, making the financial results the dominant disclosure. The CEO transition, though material, is secondary to the earnings content.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-08-13
EX-99.1
This is a news release dated August 13, 2026, announcing Telesat's financial results for the three and six months ended June 30, 2026. The exhibit discloses consolidated revenue of $79 million (Q2 2026) and $167 million (H1 2026), adjusted EBITDA figures, net losses, and segment performance, along with balance sheet data and forward guidance. This is a classic earnings release announcing periodic financial results, material to investors assessing the company's operational and financial performance.
View raw filing on EDGAR →